As winter settles over Australia, it's not just the drop in temperature we notice—there's also a sharp rise in respiratory ...

The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that’s the No. 1 ...

The agency’s decision to clear Moderna’s shot for use in certain younger adults is a much-needed win for a company that’s ...

THURSDAY, June 12, 2025 (HealthDay News) — A newly approved shot could soon help protect babies from respiratory syncytial ...

Expanded indication builds on existing U.S. FDA approval of mRESVIA for adults aged 60 and older CAMBRIDGE, MA / ACCESS ...

Scientists and analysts express concern that the newly appointed members—which include known anti-vaxxers—could relitigate ...

The FDA expanded the approval of Moderna’s RSV vaccine, extending the license to include more adults and giving the company a welcome win.

RSV seasons ended earlier than usual in 2022-23 and 2023-24, and typical human hMPV circulation patterns have returned since the COVID-19 pandemic.

HHS Secretary Robert F. Kennedy Jr named 8 new members to the CDC’s Advisory Committee on Immunization Practices.

The global respiratory syncytial virus respiratory syncytial virus treatment market is undergoing rapid growth, driven by rising vaccine uptake, impr ...